Bedaquiline (Sirturo®)

Assessment Status Rapid Review complete
Drug Bedaquiline
Brand Sirturo®
Indication For use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Assessment Process
Rapid review commissioned 23/01/2015
Rapid review completed 20/02/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended

Full HTA not required.  The NCPE however recommend that if reimbursed that use of bedaquiline be subject to certain conditions.